12.09.2022 • NewsIMCDCoatingsautomotive

IMCD Buys Japan’s Kuni Chemical

IMCD has taken over Japanese specialty distribution company Kuni Chemical for an undisclosed sum. Kuni specializes in industrial applications that range from coatings and construction to automotive and packaging materials.

Based in Osaka, Kuni posted revenues of approximately €18 million last year and employs 28 staff.

“IMCD Japan was established as a greenfield in 2016, and this acquisition marks a major milestone as we continue to grow in the country,” said Shunsaku Kubo, managing director of IMCD Japan. “Kuni Chemical adds a new business segment to IMCD with an entry into the Japanese coatings and construction markets and also complements the portfolio of our advanced materials business.”

The acquisition is the second in just a few weeks, with IMCD announcing in late August that it had agreed to buy PromaPlast, a Mexico-based distributor of advanced materials.

Author: Elaine Burridge, Freelance Journalist

In picture from left to right: Laurens Dalmijn, General Counsel of IMCD Group;...
In picture from left to right: Laurens Dalmijn, General Counsel of IMCD Group; Shunsaku Kubo, Managing Director of IMCD Japan; Kengo Matsubara, President of Kuni Chemical; Shinichi Hotta, President of Japan Private Equity Co.,Ltd.; Tatsuya Watanabe, CPA of Japan Private Equity Co.,Ltd. © Kuni/IMCD

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read